moderna inc.

Moderna CEO Stéphane Bancel explains how technology from a promising new melanoma vaccine with Merck could help treat and defeat other diseases like lung, prostate and breast cancers.

COVID-19 vaccine maker Moderna's shares fell on Thursday following the release of the company's third-quarter earnings, which showed a decline in revenue.

With COVID cases on the rise in China, the government has approved Livzon Pharmaceutical's COVID-19 vaccine as a booster, in hopes of having as many people boosted as possible.

The Centers for Disease Control and Prevention gave final approval to updated COVID-19 vaccines targeting the dominant omicron variant on Thursday.

According to the White House's COVID-19 response coordinator Dr. Ashish Jha, the U.S has begun distributing COVID-19 vaccines for children as young as six months.

Pfizer and Moderna's vaccines for children as young as 6 months old could be available next week after an FDA advisory panel recommended them on Wednesday.

The FDA's advisory committee on vaccines unanimously recommended Moderna's COVID-19 vaccine for kids between the ages of 6 and 17 on Tuesday.

Moderna said its bivalent COVID booster candidate that targets omicron demonstrates "superior antibody response" against the variant one month after it is given.

Moderna said Wednesday that revenue from its COVID-19 vaccine sales helped the company to triple its net income in a better-than-expected first quarter.

Moderna faces multiple lawsuits over its COVID-19 vaccine which could leave taxpayers paying the tab.